Adding Xpovio (selinexor) to Velcade (bortezomib) and low-dose dexamethasone significantly extends survival without signs of disease worsening in people with…
Myeloma
With an emphasis on the ability of patients and caregivers to adapt to challenges, the International Myeloma Foundation (IMF) is seeking to raise awareness…
In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them…
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc), in combination with Pomalyst (pomalidomide) and dexamethasone,…
One of the most common genomic defects in multiple myeloma patients is the loss of one copy of chromosome 13, and researchers now suggest that…
Cellectar Biosciences’ lead candidate CLR 131 safely and effectively prevents disease progression or reduces tumors in people with hard-to-treat multiple myeloma, according…
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in…
Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive…
Janssen‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone continues to lead to strong and durable responses, and…
KP1237, an experimental therapy by Kleo Pharmaceutical that harnesses the body’s natural antibodies to fight cancers, will soon enter clinical testing for…
